MX2017010009A - Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas. - Google Patents

Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas.

Info

Publication number
MX2017010009A
MX2017010009A MX2017010009A MX2017010009A MX2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A
Authority
MX
Mexico
Prior art keywords
influenza
binding molecules
directed against
virus strain
phylogenetic group
Prior art date
Application number
MX2017010009A
Other languages
English (en)
Inventor
Vogels Ronald
Heinz Edward Friesen Robert
Brandenburg Boerries
A Kolkman Joost
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2017010009A publication Critical patent/MX2017010009A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Abstract

La presente invención se refiere a moléculas de unión monoméricas y multiméricas que pueden unirse específicamente a hemaglutinina (HA) de al menos dos cepas del virus influenza A, comprendiendo dichas cepas HA de dos subtipos de HA diferentes del grupo filogenético 2; o que pueden unirse específicamente a hemaglutinina (HA) de al menos una cepa del virus influenza A del grupo filogenético 1 y al menos una cepa del virus influenza A del grupo filogenético 2; o que pueden unirse específicamente a hemaglutinina (HA) de al menos una cepa del virus influenza B. Las moléculas de unión preferiblemente también pueden neutralizar al menos dos cepas del virus influenza A del grupo filogenético 2; o pueden neutralizar al menos una cepa del virus influenza A del grupo filogenético 1 y al menos una cepa del virus influenza A del grupo filogenético 2; o pueden neutralizar específicamente al menos una cepa del virus influenza B.
MX2017010009A 2015-02-05 2016-02-05 Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas. MX2017010009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153957 2015-02-05
PCT/EP2016/052556 WO2016124768A1 (en) 2015-02-05 2016-02-05 Binding molecules directed against influenza hemagglutinin and uses thereof

Publications (1)

Publication Number Publication Date
MX2017010009A true MX2017010009A (es) 2017-10-24

Family

ID=52484335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010009A MX2017010009A (es) 2015-02-05 2016-02-05 Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas.

Country Status (17)

Country Link
US (3) US10370435B2 (es)
EP (1) EP3253411A1 (es)
JP (2) JP6772157B2 (es)
KR (1) KR20170107562A (es)
CN (1) CN107207611B (es)
AU (1) AU2016214304B2 (es)
BR (1) BR112017016417A2 (es)
CA (1) CA2975655C (es)
EA (1) EA038407B1 (es)
HK (1) HK1243925A1 (es)
IL (1) IL253653B (es)
MX (1) MX2017010009A (es)
MY (1) MY186585A (es)
PH (1) PH12017501216A1 (es)
SG (2) SG11201705614QA (es)
WO (1) WO2016124768A1 (es)
ZA (1) ZA201705300B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
KR20170107562A (ko) * 2015-02-05 2017-09-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 적혈구응집소에 대한 결합 분자 및 이의 용도
CA2985081A1 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CN110234337A (zh) * 2016-10-27 2019-09-13 扬森疫苗与预防公司 中和流感病毒的化合物
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS CIBLANG PSMA AND METHODS OF USE
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
CA3053399A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG10201913833PA (en) * 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
MX2020003856A (es) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc Proteinas de union a antigenos de maduracion de celulas b.
JP7162190B2 (ja) * 2018-07-17 2022-10-28 パナソニックＩｐマネジメント株式会社 インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法
US20220017626A1 (en) * 2018-09-21 2022-01-20 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP4106806A1 (en) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
JP2023551666A (ja) * 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド Ａ型インフルエンザウイルスに対する抗体
CA3174330A1 (en) * 2021-03-31 2022-09-30 Shugang YAO Binding agents targeting tumors and/or immune cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
GB0522460D0 (en) 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
EP3424526A1 (en) * 2008-06-05 2019-01-09 Ablynx NV Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010037046A1 (en) * 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8563305B2 (en) 2009-04-30 2013-10-22 Oklahoma Medical Research Foundation Rapid generation of antibodies
CN102276719B (zh) * 2010-06-09 2014-12-24 中国科学院生物物理研究所 禽流感病毒单域抗体、五聚抗体及其制备和应用
CN102023212B (zh) 2010-09-28 2014-04-02 汕头大学医学院 一种流感病毒神经氨酸酶抗体的快速检测方法
CN103906763B (zh) * 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
EP3812397A1 (en) * 2011-07-18 2021-04-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
JP6328061B2 (ja) 2012-03-08 2018-05-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｂ型インフルエンザウイルスに結合して中和することができるヒト結合分子およびその使用
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
WO2014161483A1 (zh) * 2013-04-02 2014-10-09 厦门大学 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
KR20170107562A (ko) * 2015-02-05 2017-09-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 적혈구응집소에 대한 결합 분자 및 이의 용도

Also Published As

Publication number Publication date
JP2018505677A (ja) 2018-03-01
US10370435B2 (en) 2019-08-06
EA201791735A1 (ru) 2017-11-30
AU2016214304B2 (en) 2021-11-11
US10703804B2 (en) 2020-07-07
ZA201705300B (en) 2021-05-26
JP6772157B2 (ja) 2020-10-21
US20190359693A1 (en) 2019-11-28
US20200299364A1 (en) 2020-09-24
EA038407B1 (ru) 2021-08-24
JP2020171288A (ja) 2020-10-22
KR20170107562A (ko) 2017-09-25
CN107207611A (zh) 2017-09-26
PH12017501216A1 (en) 2018-01-15
AU2016214304A1 (en) 2017-07-20
MY186585A (en) 2021-07-28
US11136379B2 (en) 2021-10-05
IL253653A0 (en) 2017-09-28
WO2016124768A1 (en) 2016-08-11
IL253653B (en) 2021-10-31
CA2975655C (en) 2023-09-19
HK1243925A1 (zh) 2018-07-27
SG10202103618XA (en) 2021-05-28
US20180016323A1 (en) 2018-01-18
BR112017016417A2 (pt) 2018-03-27
EP3253411A1 (en) 2017-12-13
SG11201705614QA (en) 2017-08-30
CA2975655A1 (en) 2016-08-11
CN107207611B (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
PH12017501216A1 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
HK1257074A1 (zh) 溶瘤病毒株
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
WO2016149710A3 (en) Hiv-1 neutralizing antibodies and uses thereof
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2015016755A (es) Reagrupamiento del virus de influenza.
BR112017010177A2 (pt) composição para tratamento de tecido
PH12016500492B1 (en) Pyridazinone compounds and uses thereof
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
MX2017015462A (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
BR112017006680A2 (pt) variantes de vírus influenza a
MY183072A (en) Methods and compositions for inducing protective immunity against filovirus infection
MY190102A (en) Tolerogenic dna vaccine
WO2016011035A3 (en) Neutralizing anti-influenza b antibodies and uses thereof
GB2548017A (en) A clip
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX363464B (es) Vacunas contra influenza h5.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
MX2017002768A (es) Agentes antivirales y usos de los mismos.
MX2019002879A (es) Compuestos novedosos y usos terapeuticos de los mismos.
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
WO2017011620A3 (en) Methods and compositions related to increasing the fidelity of influenza a virus for vaccine development